Aditi Shastri
Director, Myelodysplastic Syndromes and Clonal Hematopoiesis · Montefiore Medical Center/Albert Einstein College of Medicine
Credentials: · · ·
History
Research
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
Blood · 2015 · 160 citations
Stem and progenitor cell alterations in myelodysplastic syndromes
Review · Blood · 2017 · First of 4 authors · 105 citations
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells
Journal of Clinical Investigation · 2018 · First of 33 authors · 87 citations
85 papers
53 papers
44 papers
38 papers
37 papers
35 papers
- IB
30 papers
30 papers · 11 as a fellow
Clinical trials
- 2024–2030
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Principal investigator · Recruiting · Phase 1
Montefiore Medical Center
- 2019–2021
Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)
Principal investigator · Withdrawn · Phase 1
Montefiore Medical Center